Bristol-Myers Squibb
1887
FOUNDED
PUBLIC
STATUS
20K-25K
EMPLOYEES
BMY
STOCK SYMBOL
50
INVESTMENTS
$44.13
SHARE PRICE
(As of Wednesday Closing)
Description
Bristol-Myers Squibb Co discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs.
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Stock Exchange
NYS
Primary Office
- 430 East 29th Street
- 14th Floor
- New York, NY 10016
- United States
+1 (800) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Bristol-Myers Squibb’s full profile, request a free trial.
Bristol-Myers Squibb Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $43.81 - $63.69 | $72.2B | $44.45 | $3.17 | 13.4M | 1.64B |
Bristol-Myers Squibb Financials Summary
|
In Thousands,
USD |
TTM
31-Mar-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 76,455,966 | 85,428,692 | 101,748,957 | 99,100,678 |
| Revenue | 23,288,000 | 22,561,000 | 20,776,000 | 19,427,000 |
| EBITDA | 7,014,000 | 6,788,000 | 6,116,000 | 6,464,000 |
| Net Income | 5,144,000 | 4,920,000 | 1,007,000 | 4,457,000 |
| Total Assets | 34,834,000 | 34,986,000 | 33,551,000 | 33,707,000 |
| Total Debt | 6,056,000 | 7,349,000 | 7,962,000 | 6,708,000 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Bristol-Myers Squibb Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Bristol-Myers Squibb‘s full profile, request access.
Request full access to PitchBookBristol-Myers Squibb Competitors (29)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Merck & Co. | Corporation | Kenilworth, NJ | 00000 | |||
| 000 00000 | Corporation | Indianapolis, IN | 00000 | 0000 | ||
| 00000 | Venture Capital-Backed | Thousand Oaks, CA | 00000 | 00.000 | 000000000000 | 00.000 |
| 000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000000 | 00.000 |
| 000000 | Formerly VC-backed | Cambridge, MA | 0000 | 000.00 | 00000000000 | 000.00 |
Bristol-Myers Squibb Investments & Acquisitions (50)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 0000000000 | 13-May-2019 | 00000 00000 00 | 000.00 | Biotechnology | |
| 0000000 | 03-Jan-2019 | 000000000000000000 | 0000 | Biotechnology | 00000000 0000000 00 |
| 0000000 | 26-Oct-2018 | 00000 00000 00 | 0000 | Drug Discovery | |
| 00000000 | 12-Oct-2018 | 0000 | 0000 | Drug Delivery | 00000 0000000 00 |
| Nektar Therapeutics | 08-Aug-2018 | PIPE | 00.000 | Biotechnology |
Bristol-Myers Squibb Exits (12)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000 000 | 19-Jul-2018 | 00000 00000 00 | 000.00 | Completed |
|
| 00000 000000000000 | 20-Jun-2011 | 00000 00000 00 | 0000 | Completed |
|
| 000000 | 05-Aug-2009 | 00000 00000 00 | 000.00 | Completed |
|
| 00000 00000000000 | 14-Nov-2007 | 00000 00000 00 | 000.00 | Completed |
|
| Corgentech | 17-Oct-2003 | Later Stage VC | 0000 | Completed |
|
Bristol-Myers Squibb Subsidiaries (8)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| IFM Therapeutics | Drug Discovery | Boston, MA | 2015 |
| 0000000 | Drug Discovery | Copenhagen North, Denmark | 0000 |
| 000000000 | Biotechnology | Lexington, MA | 0000 |
| 0000000-00000 0000 | Foundation | New York, NY | 0000 |
| 000000000000 | Drug Discovery | Seattle, WA | 0000 |
Bristol-Myers Squibb Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Bristol-Myers Squibb‘s full profile, request access.
Request full access to PitchBookBristol-Myers Squibb Executive Team (43)
17 Former Executives
You’re viewing 5 of 43 executives. Get the full list »Bristol-Myers Squibb Board Members (8)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| 0000 0000 | Self | Board Member | 000 0000 | |
| 000000 0000000 | Self | Board Member | 000 0000 | |
| 00000000 0000000 00 | Bristol-Myers Squibb | Chairman of the Board and Chief Executive Officer | 000 0000 | |
| 0000000 000000000 | Self | Board Member | 000 0000 |
4 Former Board Members
You’re viewing 4 of 8 board members. Get the full list »